CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

May 29, 2019

|

NEW YORK (GenomeWeb) – Researchers from the University of California, San Francisco used a genome-scale CRISPR interference (CRISPRi) functional genomics platform to systematically identify genetic interactions with a mutant form of KRAS called KRAS^G12C, and found combination therapies that target genes involved in its activity.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

To read the full story....

Breaking News

CAR T-Cell Therapy Shows Signs of Anti-Tumor Activity in Pediatric Neuroblastoma Patients

Genetic Testing Challenges in Oncology: BRCA2-Positive Healthy Young Man Recommended Mastectomy

PMV Pharma Begins Trial of Investigational Drug in p53-Mutated Cancers

Persephone Biosciences Launches Study to Assess Microbiome's Role in Cancer Treatment Response

Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

Featured White Papers

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

What's Popular?

CAR T-Cell Therapy Shows Signs of Anti-Tumor Activity in Pediatric Neuroblastoma Patients

Genetic Testing Challenges in Oncology: BRCA2-Positive Healthy Young Man Recommended Mastectomy

FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

Tumor, Germline Testing of Cancer Patients Can Give Discordant Results

Sponsorships